Table 2.
Results of anti-dsDNA testing according to disease classification in ANA-positive subjects
| Anti-dsDNA (ELISA) | Anti-dsDNA (EliA) | |||
| Disease classification | Percentage positive | Titre (IU) (SD) | Percentage positive | Titre (IU) (SD) |
| SLE (n = 39) | 79 | 171 (51) | 44 | 138 (196) |
| SS (n = 22) | 18 | 152 (70) | 12 | 89 (56) |
| RA (n = 17) | 29 | 200 (0) | 6 | 48 (2) |
| UCTD (n = 9) | 22 | 194 (8) | 22 | 59 (0.2) |
| Various (n = 57)a | 35 | 143 (82) | 22 | 36 (49) |
Values represent mean values (SD) unless otherwise indicated. aIncludes patients with viral hepatitis, angina pectoris, apnoea syndrome, arthralgia/lumbago, asthma/bronchitis, cataract/cornea bleeding, claudicatio intermittens, cerebrovascular accident, epilepsy, erythematosus nodosum, fibromyalgia, haematuria, headache, hypothyroidism, urinary tract infections, solid cancer, menisc rupture, migraine, myasthenia gravis, panniculitis, psoriasis, rash, urine incontinence, observation, periorbital edema, and Stevens-Johnson syndrome. Anti-dsDNA, anti-double-stranded DNA; EliA, fluorescence enzyme immunoassay test for anti-double-stranded DNA (Phadia GmbH); ELISA, enzyme-linked immunosorbent assay; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus; SS, Sjøgren's syndrome; UCTD, unclassified connective tissue disease.